Pharma News

Pharmacy council of India is preparing for the exit exam for Diploma pharmacy. PCI invites Government faculty for panel empanelment of Exit Exam.

PCI (Pharmacy council of India) said in a notification that this is to bring to kind information that Exit Examination for Diploma in Pharmacy has to be conducted. Faculty from Government and Government Aided colleges are hereby informed to fill the form for being considered as an expert.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The cellular glitches underlying a rare genetic disorder called activated PI3K Delta syndrome 2 (APDS2) have been identified by researchers at the Garvan Institute of Medical Research. The disorder is caused by genetic variations that disrupt immune cell signalling through a protein called PI3K.

A research team at Duke Health has identified a set of biomarkers that could help distinguish whether cysts on the pancreas are likely to develop into cancer or remain benign.

Appearing online March 17 in the journal Science Advances, the finding marks an important first step toward a clinical approach for classifying lesions on the pancreas that are at highest risk of becoming cancerous, potentially enabling their removal before they begin to spread.

Cancer treatments have long been moving toward personalization finding the right drugs that work for a patient’s unique tumor, based on specific genetic and molecular patterns. Many of these targeted therapies are highly effective, but aren’t available for all cancers, including non-small cell lung cancers (NSCLCs) that have an LKB1 genetic mutation.

A new substance has proven useful for treating staphylococcus infections in people with skin lymphoma. This is good news for the patients, but also for the global threat of antibiotics resistance.

The gut is home to a cast of microbes that influence health and disease.

Sanofi announces that it will cut the list price of Lantus (insulin glargine injection) 100 Units/mL, its most widely prescribed insulin in the U.S., by 78 percent. The company also will establish a 35 USD cap on out-of-pocket costs for Lantus for all patients with commercial insurance, underscoring its longstanding commitment to offer affordable access to medicines.

Strengthening the Bangladesh pharma manufacturing capabilities 14th ASIA PHARMA EXPO 2023 exhibition celebrating successful 21 years in Bangladesh offered business opportunities to 658 companies from 32 countries